Q32 Bio and Homology Medicines Announce Merger Agreement

Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. (Nasdaq: FIXX), announces they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Q32 Bio’s wholly owned clinical development candidates for the treatment of autoimmune and inflammatory diseases. Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol “QTTB”.

Read the full article: Q32 Bio and Homology Medicines Announce Merger Agreement //

Source: https://www.prnewswire.com/news-releases/q32-bio-and-homology-medicines-announce-merger-agreement-301990064.html

Leave a Comment

Your email address will not be published.

Scroll to Top